RxDoctor Payments Data

Aimee Park, MD

Cardiovascular Disease · Frederick, MDNPI 1265435978

Payments from drug & device makers

$676in general payments, 2019–2025

Across 30 payments — averaging $22.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$176
  • Amarin Pharma, Inc.$105
  • Novartis$98
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$54
  • Kowa Pharmaceuticals America, Inc.$39
  • Actelion Pharmaceuticals US, Inc.$27
  • plus $176 from 10 others

What the payments were for

  • Food & beverage$66498%
  • Education$122%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$676 in reported general payments places this provider in the 35th percentile of 507 cardiovascular disease providers in Maryland.

See all cardiovascular disease providers in Maryland

Medicare billing

Part B allowed, 2024
$742,600
Medicare patients
1,930
Services billed
6,392

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban273$326,331
EntrestoSacubitril/Valsartan180$181,363
Repatha SureclickEvolocumab144$164,236
XareltoRivaroxaban70$95,448
Praluent PenAlirocumab22$24,691
MultaqDronedarone Hcl11$20,510
VascepaIcosapent Ethyl28$17,958
Repatha SyringeEvolocumab11$17,678
Ezetimibe431$16,964
BrilintaTicagrelor12$15,252
Metoprolol Succinate908$15,097
Ranolazine ErRanolazine105$10,404
Atorvastatin Calcium789$9,954
Rosuvastatin Calcium424$8,775
Pravastatin Sodium165$4,156

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$13$326,331273 claims
NovartisEntresto$98$181,363180 claims
Johnson & JohnsonXarelto$17$95,44870 claims
Sanofi-aventis U.S. LLCMultaq$16$20,51011 claims
AstraZenecaBrilinta$14$15,25212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 507 cardiovascular disease providers in Maryland.

Other cardiovascular disease in Frederick

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →